Global Life Sciences Ventures

GLSV led the series A financing of GlycArt in November 2003, held a supervisory board position and also played an active role in initiating the trade sale process In 2005 Roche paid approximately CHF 235 million for the acquisition of the company The transaction was managed by ABN AMRO

08 12 2015 Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration more

30 11 2015 Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration more

19 11 2015 Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program more

30 09 2015 Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team more

15 09 2015 Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference more

18 08 2015 Pieris Pharmaceuticals Appoints Louis A Matis, M D , as Chief Development Officer more

28 07 2015 Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock more

08 07 2015 Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics more

06 07 2015 Pieris Pharmaceuticals Closes Public Offering of Common Stock more

30 06 2015 Pieris Pharmaceuticals Prices Public Offering of Common Stock more

10 06 2015 Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia more

21 05 2015 Nabriva Therapeutics appoints Elyse Seltzer, MD, as Chief Medical Officer more